Home Respiratory Rehabilitation in Advanced Lung Cancer Chemotherapy Per os

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-03

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The feasibility and impact of respiratory rehabilitation (RR) in patients with advanced or metastatic (EGF-R WT or mutated) non-small cell lung cancer treated with oral targeted therapy including Inhibitors of EGF-R tyrosine kinases (TKI) and ALK inhibitors.

These patients will benefit, at the beginning of the chemotherapy whatever the treatment line, of a respiratory rehabilitation. The respiratory rehabilitation takes place at the patient's home with the HAD's cooperation 3 hours per week, divided into 2 or 3 sessions. There is associated educational, nutritional and psychological support for a total duration of 8 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility of a 8-week Telerehabilitation Program for Patients With Thoracic Neoplasia Receiving Chemotherapy

NCT02716493

Lung Cancer

UNKNOWN NA

Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation

NCT02017925

Cachexia Fatigue Pulmonary Complications +5 more

WITHDRAWN NA

Exercise and Nutritional Rehabilitation in Patients With Cancer

NCT03316157

Cachexia; Cancer Diet Modification Physical Activity +1 more

COMPLETED NA

Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience

NCT03724331

Fatigue Self Efficacy Quality of Life +3 more

COMPLETED NA

Prehabilitation & Rehabilitation in Oncogeriatrics: Adaptation to Deconditioning Risk and Accompaniment of Patients' With Cancer

NCT03659123

Old Injury

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Patients with advanced or metastatic non-small cell lung cancer treated with oral targeted therapy (tyrosine kinase (TKI) inhibitors of EGF-R and ALK inhibitors), regardless of the treatment line.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

8 weeks Respiratory rehabilitation

Group Type EXPERIMENTAL

Respiratory rehabilitation

Intervention Type OTHER

It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Respiratory rehabilitation

It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with advanced or metastatic lung cancer
* In the course of treatment by oral chemotherapy of oral targeted therapy (tyrosine kinase inhibitor) in 1st, 2nd, 3rd line or more at the time of their inclusion
* Diagnosis of CP retained after multidisciplinary discussion of patient records

Exclusion Criteria

* Any residual toxicity of a previous antineoplastic treatment, grade\> 2.
* Cardio-respiratory contraindications to exercise re-training:
* Angina unstable
* Recent infarct
* Tight aortic stenosis
* Unsteady heart failure
* Pericarditis, endocarditis, myocarditis
* Evolutionary thromboembolic disease
* Ventricular aneurysm
* Intra ventricular thrombus
* Uncontrolled rhythm disorders
* Instability of the respiratory state defined by uncompensated respiratory acidosis
* Carcinological contraindications:
* Bone metastases at risk of fracture and / or algae despite optimal analgesic treatment, symptomatic central nervous system metastases
* Presence of anemia (Hb \<8g / dl or \<10g / dl if patient with previous cardiac history), thrombocytopenia (\<100,000 platelets / mm3)
* Chimio toxicity (neurological, cardiac) according to the investigator's assessment
* Neuromuscular contraindications:
* Neuromuscular and / or osteo-articular disease making it impossible to re-train
* Severe cognitive impairment
* Patient under tutorship or curatorship

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No